CRITERIA FOR DIFFERENTIAL ANALYSIS OF MAIN LABORATORY MARKERS OF HEMOLYTIC ANEMIA
Keywords:
The incidence of autoimmune hemolytic anemiaAbstract
In the field of modern hematology and clinical laboratory diagnostics, the problem of hemolytic anemia (HA) remains one of the most complex and urgent areas for medical scientists, researchers and practitioners. According to the statistics of the World Health Organization and extensive epidemiological studies conducted in recent years, hemolytic anemia accounts for 5.3% of blood system diseases and 11.5% of all anemia cases recorded worldwide[1]. Pathological rapid destruction (hemolysis) of erythrocytes (red blood cells) before their physiological lifespan (normally about 100-120 days) triggers extremely severe cascade reactions in the body. As a result of premature damage and destruction of erythrocytes, the oxygen-carrying capacity of the blood decreases sharply, which leads to severe hypoxia, ischemia and multiorgan failure of vital organs such as the brain, heart, kidneys[4].
References
[1] Barcellini, W., Fattizzo, B., Zaninoni, A., Rabbolini, D., & Zanella, A. (2015). Treatment of autoimmune hemolytic anemias. Haematologica, 100(11), 1413–1422.https://doi.org/10.3324/haematol.2015.130914
[2] Sudulagunta, SR, Sodalagunta, MB, Kumbhat, M., & Settikere Nataraju, A. (2017). Warm autoimmune hemolytic anemia. Oxford Medical Case Reports, 2017(2), omx003.https://doi.org/10.1093/omcr/omx003
[3] Kalfa, TA (2022). Laboratory evaluation of immune hemolytic anemias. StatPearls. National Library of Medicine.https://www.ncbi.nlm.nih.gov/books/NBK606096/
[4] Schick, P. (2018). Hemolytic anemia: evaluation and differential diagnosis. American Family Physician, 98(6), 354–361.https://www.aafp.org/pubs/afp/issues/2018/0915/p354.html
[5] Aladjidi, N., Leverger, G., Leblanc, T., Picat, MQ, Michel, G., Bertrand, Y., & Guitton, C. (2011). New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica, 96(5), 655–663.https://doi.org/10.3324/haematol.2010.036053
[6] Riskin, A., Gery, N., Arnon, S., Bader, D., Kugelman, A., & Litmanowitz, I. (2022). Glucose-6-phosphate dehydrogenase deficiency and neonatal hyperbilirubinemia: Insights on pathophysiology, diagnosis, and gene variants in disease heterogeneity. Frontiers in Pediatrics, 10, 875877.https://doi.org/10.3389/fped.2022.875877
[7] Gehrs, BC, & Friedberg, RC (2002). Autoimmune hemolytic anemia. American Journal of Hematology, 69(4), 258–271.https://doi.org/10.1002/ajh.10000
[8] Hill, QA, Stamps, R., Massey, E., Grainger, JD, Provan, D., Hill, A., & British Society for Haematology (2017). The diagnosis and management of primary autoimmune hemolytic anemia. British Journal of Hematology, 176(3), 395–411.https://doi.org/10.1111/bjh.14478
[9] Brodsky, RA (2015). Warm autoimmune hemolytic anemia. New England Journal of Medicine, 373(13), 1253–1264.https://doi.org/10.1056/NEJMcp1509507
[10] Zangeneh, MM, Zangeneh, A., Pirabbasi, E., Moradi, R., & Lagzian, A. (2020). Application of natural compounds-based gold nanoparticles for the treatment of hemolytic anemia in an anemic mouse model. Applied Organometallic Chemistry, 34(2), e5330.https://doi.org/10.1002/aoc.5330
[11] Zangeneh, MM, Zangeneh, A., & Moradi, R. (2019). Hydrophilic extract of Pistacia vera pericarp protects against phenylhydrazine-induced hepatotoxicity and hemolytic anemia. BMC Complementary Medicine and Therapies, 19, 210.https://pmc.ncbi.nlm.nih.gov/articles/PMC11287025/
[12] Shanmuga Priya, M., Hemalatha, T., Thiruvenkatam, R., & Panneerselvam, A. (2017). Evaluation of antioxidant and anti-anaemic potential of Moringa oleifera on phenylhydrazine-induced hematotoxicity. International Journal of Pharmacy and Pharmaceutical Sciences, 9(4), 104–109.https://doi.org/10.22159/ijpps.2017v9i4.17228
[13] Goorani, S., Zangeneh, MM, Zangeneh, A., Moradi, R., Saneei, S., & Tahvilian, R. (2019). Ziziphora clinopodioides Lam leaf aqueous extract mediated novel green synthesis of iron nanoparticles and its anti-hemolytic anemia potential: A chemobiological study. Arabian Journal of Chemistry, 12(8), 2600–2612.https://doi.org/10.1016/j.arabjc.2019.07.009
[14] Gheith, I., El-Mahmoudy, A., & Salem, A. (2019). Application of natural compounds-based gold nanoparticles for the treatment of hemolytic anemia in an anemic mouse model: Formulation of a novel drug from the relationship between the nanotechnology and hematology sciences. Artificial Cells, Nanomedicine, and Biotechnology, 47(1), 2455–2467.https://doi.org/10.1080/21691401.2019.1613921
[15] Garratty, G. (2010). Drug-induced immune hemolytic anemia. Hematology: American Society of Hematology Education Program, 2010(1), 73–79.https://pubmed.ncbi.nlm.nih.gov/20008184/
[16] Berentsen, S., & Barcellini, W. (2021). Autoimmune hemolytic anemias. New England Journal of Medicine, 385(15), 1407–1419.https://doi.org/10.1056/NEJMra2033982
[17] Nwanna, EE, Ibukun, EO, & Oboh, G. (2016). Evaluation of antioxidant and anti-anaemic potential of Moringa oleifera parts on phenylhydrazine-induced hematotoxicity in male Wistar rats. Comparative Clinical Pathology, 25(6), 1185–1193.https://pdfs.semanticscholar.org/99be/d1c20e839d6bd290cbdb8dde2c1389dda006.pdf
[18] Dhaliwal, G., Cornett, PA, & Tierney, LM (2004). Hemolytic anemia. American Family Physician, 69(11), 2599–2606.https://www.aafp.org/pubs/afp/issues/2004/0601/p2599.html
[19] Pivkin, IV, Peng, Z., Karniadakis, GE, Buffet, PA, Dao, M., & Suresh, S. (2016). Biomechanics of red blood cells in human spleen and consequences for physiology and disease. Proceedings of the National Academy of Sciences, 113(28), 7804–7809.https://doi.org/10.1073/pnas.1606751113
[20] Berentsen, S. (2021). Complement activation and inhibition in autoimmune hemolytic anemia: Focus on cold agglutinin disease. Seminars in Hematology, 58(3), 178–185.https://doi.org/10.1053/j.seminhematol.2021.06.003
[21] Watchko, JF, & Tiribelli, C. (2013). Bilirubin-induced neurological damage: Mechanisms and management approaches. New England Journal of Medicine, 369(21), 2021–2030.https://doi.org/10.1056/NEJMra1308124
[22] Patel, B., & Patel, J. (2021). Hepatic-related hematological disorders in children. World Journal of Hepatology, 13(12), 1708–1722.https://doi.org/10.4254/wjh.v13.i12.1708
[23] Fattizzo, B., Giannotta, JA, Cecchini, L., Cantoni, S., & Barcellini, W. (2024). Autoimmune hemolytic anemias: Classifications, pathophysiology, diagnoses and management. International Journal of Molecular Sciences, 25(8), 4296.https://doi.org/10.3390/ijms25084296
[24] Jager, U., Barcellini, W., Broome, CM, Gertz, MA, Hill, A., Hill, QA, & Berentsen, S. (2020). Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Reviews, 41, 100648.https://doi.org/10.1016/j.blre.2019.100648
[25] ARUP Laboratories (2024). Hemolytic anemias: Choose the right test. ARUP Consult.https://arupconsult.com/content/hemolytic-anemias
[26] Roth, A., Barcellini, W., D'Sa, S., Miyakawa, Y., Broome, CM, Michel, M., & Berentsen, S. (2021). Sutimlimab in cold agglutinin disease. New England Journal of Medicine, 384(14), 1323–1334.https://doi.org/10.1056/NEJMoa2027760
[27] Kato, GJ, McGowan, W., Machado, RF, Little, JA, Taylor, J., Morris, CR, & Gladwin, MT (2006). Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood, 107(6), 2279–2285.https://doi.org/10.1182/blood-2005-06-2373
[28] Cutter, DJ (2023). Overview and differential diagnosis of hemolytic anemia in adults. UpToDate / The Blood Project.https://www.thebloodproject.com/cases-archive/65-year-old-woman-with-positive-hemolytic-markers/labs/
[29] Hill, A., & Hill, QA (2022). Autoimmune hemolytic anemia. Hematology: American Society of Hematology Education Program, 2018(1), 382–389.https://doi.org/10.1182/asheducation-2018.1.382
[30] Klatt, EC (2021). Red blood cell contribution to hemostasis. ResearchGate – Journal of Thrombosis and Haemostasis, 19(3), 512–516.https://www.researchgate.net/publication/350565466
[31] Hosing, C. (2024). Hematopoietic stem cell transplantation for refractory autoimmune cytopenias. MD Anderson Cancer Center Faculty Resources.https://faculty.mdanderson.org/profiles/chitra_hosing.html
[32] Ozelle Medical (2025). Blood test machine market: Transforming diagnostics with AI-powered innovation. Ozelle Medical Technology Review.https://ozellemed.com/en/blood-test-machine-market-transforming-diagnostics-with-ai-powered-innovation/
[33] Li, Y., Liu, X., Zhang, X., Wang, H., & Chen, J. (2025). Evaluation of MC-80 automatic blood cell morphology analyzer in identifying the morphology of blood cells in patients with hematological diseases and normal samples. Clinical Chemistry and Laboratory Medicine.https://pubmed.ncbi.nlm.nih.gov/40696611/
[34] Elsafty, AE (2024). AI analysis of red blood cells: A Q&A with Dr. Ahmed Elnady Elsafty. Critical Values – ASCP.https://criticalvalues.org/news/all/2024/11/19/ai-analysis-of-red-blood-cells-aqa-with-dr.-ahmed-elnady-elsafty
[35] Alzahrani, M., Alsubaie, T., Almushaikah, A., & Almutairi, A. (2025). AI-driven automated blood cell anomaly detection: Enhancing diagnostics and telehealth in hematology. Journal of Imaging, 11(5), 157.https://doi.org/10.3390/jimaging11050157
[36] Grossman, BJ, Lemaire, SL, & Power, LJ (2026). A 24-year-old man with severe hemolytic anemia and variable Coombs test results. Cleveland Clinic Journal of Medicine, 93(3), 159–164.https://doi.org/10.3949/ccjm.93a.24079
[37] Fattizzo, B., & Barcellini, W. (2025). Beneath the surface in autoimmune hemolytic anemia: Pathogenetic networks, therapeutic advances and open questions. Frontiers in Immunology, 16, 1624667.https://doi.org/10.3389/fimmu.2025.1624667
[38] Cheng, MM, & Ipe, TS (2024). Autoimmune hemolytic anemia with an initially negative direct antiglobulin test: A diagnostic challenge. Blood, 144(Supplement 1), 6447.https://doi.org/10.1182/blood-2024-200099
[39] Barcellini, W., & Fattizzo, B. (2020). The changing landscape of autoimmune hemolytic anemia. Frontiers in Immunology, 11, 946.https://doi.org/10.3389/fimmu.2020.00946
[40] Garratty, G., & Arndt, PA (2014). Drugs that have been shown to cause drug-induced immune hemolytic anemia: An update. Immunohematology, 30(2), 66–79.https://doi.org/10.21307/immunohematology-2019-071
[41] Koseki, K., Hashimoto, C., Onodera, M., & Sakamaki, H. (2021). Severe drug-induced immune hemolytic anemia due to cefmetazole: A case report. Annals of Hematology, 101(1), 223–225.https://pubmed.ncbi.nlm.nih.gov/34672255/
[42] Ramirez, A., & Johnson, L. (2026). Review of the diagnosis, treatment, and outcomes of immunotherapy-associated autoimmune hemolytic anemia. Clinical Laboratory Science.https://doi.org/10.29074/ascls.2025003286
[43] Mehta, A., & Mason, PJ (2022). Severe G6PD deficiency leads to recurrent infections and defects in ROS production: Case report and literature review. Frontiers in Genetics, 13, 1035673.https://doi.org/10.3389/fgene.2022.1035673
[44] Guo, X., Yu, B., Li, Z., Huang, Z., Chen, J., & Ma, L. (2018). A review on dapsone hypersensitivity syndrome among Chinese patients with an emphasis on preventing adverse drug reactions with genetic testing. American Journal of Tropical Medicine and Hygiene, 96(5), 1014–1021.https://doi.org/10.4269/ajtmh.17-0440
[45] Staines, HM, & Krishna, S. (2024). Recent advances in the treatment of malaria. Pharmaceutics, 16(11), 1416.https://doi.org/10.3390/pharmaceutics16111416
[46] Al-Naama, LM, Hassan, MK, & Mehdi, JK (2025). The impact of glucose-6-phosphate dehydrogenase deficiency on liver function and enzymatic antioxidants in patients from Basrah Province. Iraqi Journal of Medical Sciences, 23(1), 45–52.https://www.researchgate.net/publication/389262492
[47] Hu, Y., Zhang, Y., Chen, X., Liu, J., & Wang, Q. (2025). G6PD deficiency as an underrecognized genetic risk factor for rare neurological disorders: Evidence from a population-based genetic analysis. Frontiers in Neurology, 16, 1490523.https://pmc.ncbi.nlm.nih.gov/articles/PMC12916064/
[48] Grace, RF, Bianchi, P., van Beers, EJ, Eber, SW, Glader, B., Yaish, HM, & Barcellini, W. (2022). Next generation sequencing for the diagnosis of hereditary hemolytic anemias including pyruvate kinase deficiency. Blood, 140(Supplement 1), 2436–2438.https://doi.org/10.1182/blood-2022-162620
[49] El-Beshbishy, HA, Singab, AN, Sinkkonen, J., & Pihlaja, K. (2006). Laboratory evidence for the hematopoietic potential of Beta vulgaris leaf and stalk extract in a phenylhydrazine model of anemia. Phytomedicine, 13(5), 324–331.https://pmc.ncbi.nlm.nih.gov/articles/PMC6190212/
[50] Okafor, AC, Anyaehie, UB, Nwadike, KI, Nweke, EU, & Nwoha, PU (2024). Studies on Amaranthus cruentus ethanolic herbal extract antianemic properties against rats' phenylhydrazine-induced anemia. International Journal of Zoological and Entomological Life Sciences, 3(1), 1–12.https://lapinjournals.com/index.php/ijzels/article/view/4
[51] El-Beshbishy, HA, Singab, AN, Sinkkonen, J., & Pihlaja, K. (2006). Laboratory evidence for the hematopoietic potential of Beta vulgaris leaf and stalk extract in a phenylhydrazine model of anemia [Research data]. ResearchGate.https://www.researchgate.net/publication/328226403
[52] Guo, L., Yuan, W., Lu, Z., & Li, C. M. (2023). Novel green synthesis of silver nanoparticles mediated by Curcumae kwangsiensis for anti-lung cancer activities: A preclinical trial study. BMC Complementary Medicine and Therapies, 23, 298.https://pmc.ncbi.nlm.nih.gov/articles/PMC10507782/
[53] Valent, P., & Lechner, K. (2008). Diagnosis and treatment of autoimmune hemolytic anemias in adults: A clinical review. Wiener Klinische Wochenschrift, 120(5–6), 136–151.https://pubmed.ncbi.nlm.nih.gov/30504336/
[54] Choudhry, A., Shafiq, M., Abdelhalim, S., & Pervaiz, A. (2024). Severe hemolysis flare of refractory warm hemolytic anemia with positive complement component C3d responsive to iptacopan with cyclophosphamide and prednisone. Blood, 144(Supplement 1), 2880.https://doi.org/10.1182/blood-2024-207162
[55] Johnson & Johnson (2025). FDA grants Priority Review for IMAAVY (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA). Johnson & Johnson Press Release.https://www.jnj.com/media-center/press-releases/fda-grants-priority-review-for-imaavy-nipocalimab-aahu-as-the-potential-first-approved-treatment-for-people-living-with-warm-autoimmune-hemolytic-anemia-waiha
[56] Johnson & Johnson (2025). Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options. Johnson & Johnson Press Release.https://www.jnj.com/media-center/press-releases/warm-autoimmune-hemolytic-anemia-waiha-research-presented-by-johnson-johnson-highlights-profound-disease-burden-and-unmet-need-for-targeted-treatment-options
[57] Barcellini, W., Fattizzo, B., & Zaninoni, A. (2025). Beneath the surface in autoimmune hemolytic anemia: Pathogenetic networks, therapeutic advances and open questions. Frontiers in Immunology, 16, 1624667.https://doi.org/10.3389/fimmu.2025.1624667
[58] Jager, U., & Lechner, K. (2019). Defining autoimmune hemolytic anemia: A systematic review of the terminology used for diagnosis and treatment. Blood Advances, 3(12), 1897–1906.https://doi.org/10.1182/bloodadvances.2019000036




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal